Use of ruxolitinib in patients with severe COVID-19
A summary of the prospective observational study by the RUXO-COVID Study Group assessing response to ruxolitinib treatment in 34 patients with COVID-19-induced severe pulmonary disease.
How should antibiotics be administered in transplant patients to reduce GvHD?
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Steering Committee member Arnon Nagler, Tel Aviv...
" The new GvHD Hub is an amazing resource for physicians and healthcare professionals in the field of GvHD. We have recently seen some great advances in this era, and the GvHD Hub is the place to go for the most up-to-date information. "